Journal of Gastroenterology

, Volume 49, Issue 7, pp 1111–1120 | Cite as

Interaction between gastric cancer stem cells and the tumor microenvironment

  • Takatsugu Ishimoto
  • Hiroshi Sawayama
  • Hidetaka Sugihara
  • Hideo Baba
Review

Abstract

Gastric cancer (GC) remains a leading cause of cancer-related deaths worldwide. Cancer stem cells (CSCs) are selectively capable of tumor initiation and are implicated in tumor relapse and metastasis, thus, governing the prognosis of GC patients. Stromal cells and extracellular matrix adjacent to cancer cells are known to form a supportive environment for cancer progression. CSC properties are also regulated by their microenvironment through cell signaling and related factors. This review presents the current findings regarding the influence of the tumor microenvironment on GC stem cells, which will support the development of novel therapeutic strategies for patients with GC.

Keywords

Cancer stem cell Tumor microenvironment Niche Gastric cancer 

References

  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.PubMedGoogle Scholar
  2. 2.
    Hohenberger P, Gretschel S. Gastric cancer. Lancet. 2003;362(9380):305–15.PubMedGoogle Scholar
  3. 3.
    Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. Cell. 2006;124(6):1111–5.PubMedGoogle Scholar
  4. 4.
    Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355(12):1253–61.PubMedGoogle Scholar
  5. 5.
    Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012;10(6):717–28.PubMedGoogle Scholar
  6. 6.
    Furth J, Kahn M. The transmission of leukaemia of mice with a single cell. Am J Cancer. 1937;31:276–82.Google Scholar
  7. 7.
    Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730–7.PubMedGoogle Scholar
  8. 8.
    Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100(7):3983–8.PubMedCentralPubMedGoogle Scholar
  9. 9.
    Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63(18):5821–8.PubMedGoogle Scholar
  10. 10.
    Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111–5.PubMedGoogle Scholar
  11. 11.
    Xu G, Shen J, Ou Yang X, et al. Cancer stem cells: the ‘heartbeat’ of gastric cancer. J Gastroenterol. 2013;48(7):781–97.PubMedGoogle Scholar
  12. 12.
    Mueller MM, Fusenig NE. Friends or foes—bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004;4(11):839–49.PubMedGoogle Scholar
  13. 13.
    Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001;411(6835):375–9.PubMedGoogle Scholar
  14. 14.
    Takaishi S, Okumura T, Tu S, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells. 2009;27(5):1006–20.PubMedCentralPubMedGoogle Scholar
  15. 15.
    Zhang C, Li C, He F, et al. Identification of CD44+CD24+ gastric cancer stem cells. J Cancer Res Clin Oncol. 2011;137(11):1679–86.PubMedGoogle Scholar
  16. 16.
    Chen T, Yang K, Yu J, et al. Identification and expansion of cancer stem cells in tumor tissues and peripheral blood derived from gastric adenocarcinoma patients. Cell Res. 2012;22(1):248–58.PubMedCentralPubMedGoogle Scholar
  17. 17.
    Han ME, Jeon TY, Hwang SH, et al. Cancer spheres from gastric cancer patients provide an ideal model system for cancer stem cell research. Cell Mol Life Sci. 2011;68(21):3589–605.PubMedGoogle Scholar
  18. 18.
    Katsuno Y, Ehata S, Yashiro M, et al. Coordinated expression of REG4 and aldehyde dehydrogenase 1 regulating tumourigenic capacity of diffuse-type gastric carcinoma-initiating cells is inhibited by TGF-beta. J Pathol. 2012;228(3):391–404.PubMedGoogle Scholar
  19. 19.
    Liu J, Ma L, Xu J, et al. Spheroid body-forming cells in the human gastric cancer cell line MKN-45 possess cancer stem cell properties. Int J Oncol. 2013;42(2):453–9.PubMedCentralPubMedGoogle Scholar
  20. 20.
    Jiang J, Zhang Y, Chuai S, et al. Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype. Oncogene. 2012;31(6):671–82.PubMedGoogle Scholar
  21. 21.
    Ohkuma M, Haraguchi N, Ishii H, et al. Absence of CD71 transferrin receptor characterizes human gastric adenosquamous carcinoma stem cells. Ann Surg Oncol. 2012;19(4):1357–64.PubMedGoogle Scholar
  22. 22.
    Jiang Y, He Y, Li H, et al. Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer. Gastric Cancer. 2012;15(4):440–50.PubMedGoogle Scholar
  23. 23.
    Hashimoto K, Aoyagi K, Isobe T, et al. Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer. Gastric Cancer. 2014;17(1):97–106.PubMedCentralPubMedGoogle Scholar
  24. 24.
    Ishimoto T, Nagano O, Yae T, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(−) and thereby promotes tumor growth. Cancer Cell. 2011;19(3):387–400.PubMedGoogle Scholar
  25. 25.
    Nagano O, Okazaki S, Saya H. Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene. 2013;32(44):5191–8.PubMedGoogle Scholar
  26. 26.
    Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121(3):335–48.PubMedGoogle Scholar
  27. 27.
    Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9(4):239–52.PubMedCentralPubMedGoogle Scholar
  28. 28.
    Guo X, Oshima H, Kitmura T, et al. Stromal fibroblasts activated by tumor cells promote angiogenesis in mouse gastric cancer. J Biol Chem. 2008;283(28):19864–71.PubMedGoogle Scholar
  29. 29.
    Worthley DL, Ruszkiewicz A, Davies R, et al. Human gastrointestinal neoplasia-associated myofibroblasts can develop from bone marrow-derived cells following allogeneic stem cell transplantation. Stem Cells. 2009;27(6):1463–8.PubMedGoogle Scholar
  30. 30.
    Quante M, Tu SP, Tomita H, et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. 2011;19(2):257–72.PubMedCentralPubMedGoogle Scholar
  31. 31.
    Shibata W, Ariyama H, Westphalen CB, et al. Stromal cell-derived factor-1 overexpression induces gastric dysplasia through expansion of stromal myofibroblasts and epithelial progenitors. Gut. 2013;62(2):192–200.PubMedGoogle Scholar
  32. 32.
    Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol. 2008;216(1):15–24.PubMedGoogle Scholar
  33. 33.
    Hasita H, Komohara Y, Okabe H, et al. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci. 2010;101(8):1913–9.PubMedGoogle Scholar
  34. 34.
    Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122(3):787–95.PubMedCentralPubMedGoogle Scholar
  35. 35.
    De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell. 2013;23(3):277–86.PubMedGoogle Scholar
  36. 36.
    Ohta M, Kitadai Y, Tanaka S, et al. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas. Int J Oncol. 2003;22(4):773–8.PubMedGoogle Scholar
  37. 37.
    Kuroda T, Kitadai Y, Tanaka S, et al. Monocyte chemoattractant protein-1 transfection induces angiogenesis and tumorigenesis of gastric carcinoma in nude mice via macrophage recruitment. Clin Cancer Res. 2005;11(21):7629–36.PubMedGoogle Scholar
  38. 38.
    Wu H, Xu JB, He YL, et al. Tumor-associated macrophages promote angiogenesis and lymphangiogenesis of gastric cancer. J Surg Oncol. 2012;106(4):462–8.PubMedGoogle Scholar
  39. 39.
    Oshima H, Matsunaga A, Fujimura T, et al. Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway. Gastroenterology. 2006;131(4):1086–95.PubMedGoogle Scholar
  40. 40.
    Oguma K, Oshima H, Aoki M, et al. Activated macrophages promote Wnt signalling through tumour necrosis factor-alpha in gastric tumour cells. EMBO J. 2008;27(12):1671–81.PubMedCentralPubMedGoogle Scholar
  41. 41.
    Yamanaka N, Morisaki T, Nakashima H, et al. Interleukin 1beta enhances invasive ability of gastric carcinoma through nuclear factor-kappaB activation. Clin Cancer Res. 2004;10(5):1853–9.PubMedGoogle Scholar
  42. 42.
    Cardoso AP, Pinto ML, Pinto AT et al (2013) Macrophages stimulate gastric and colorectal cancer invasion through EGFR Y, c-Src, Erk1/2 and Akt phosphorylation and smallGTPase activity. Oncogene.Google Scholar
  43. 43.
    Zhuang Y, Peng LS, Zhao YL, et al. Increased intratumoral IL-22-producing CD4(+) T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survival. Cancer Immunol Immunother. 2012;61(11):1965–75.PubMedGoogle Scholar
  44. 44.
    Zhuang Y, Peng LS, Zhao YL, et al. CD8(+) T cells that produce interleukin-17 regulate myeloid-derived suppressor cells and are associated with survival time of patients with gastric cancer. Gastroenterology. 2012;143(4):951 e8–962 e8.Google Scholar
  45. 45.
    Leedham SJ, Brittan M, Preston SL, et al. The stomach periglandular fibroblast sheath: all present and correct. Gut. 2006;55(2):295–6.PubMedCentralPubMedGoogle Scholar
  46. 46.
    Hoffmann W. Stem cells, self-renewal and cancer of the gastric epithelium. Curr Med Chem. 2012;19(35):5975–83.PubMedGoogle Scholar
  47. 47.
    Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 2006;66(9):4553–7.PubMedGoogle Scholar
  48. 48.
    Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8(10):755–68.PubMedGoogle Scholar
  49. 49.
    Boral D, Nie D. Cancer stem cells and niche mircoenvironments. Front Biosci. 2012;4:2502–14.Google Scholar
  50. 50.
    Yi SY, Hao YB, Nan KJ, Fan TL. Cancer stem cells niche: a target for novel cancer therapeutics. Cancer Treat Rev. 2013;39(3):290–6.PubMedGoogle Scholar
  51. 51.
    Borovski T, De Sousa EMF, Vermeulen L, Medema JP. Cancer stem cell niche: the place to be. Cancer Res. 2011;71(3):634–9.PubMedGoogle Scholar
  52. 52.
    Hasegawa T, Yashiro M, Nishii T et al (2013) Cancer-associated fibroblasts might sustain the stemness of scirrhous gastric cancer cells via transforming growth factor-beta signaling. Int J Cancer: Journal international du cancer.Google Scholar
  53. 53.
    Soeda A, Park M, Lee D, et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene. 2009;28(45):3949–59.PubMedGoogle Scholar
  54. 54.
    Ma Y, Liang D, Liu J, et al. Prostate cancer cell lines under hypoxia exhibit greater stem-like properties. PLoS One. 2011;6(12):e29170.PubMedCentralPubMedGoogle Scholar
  55. 55.
    Yeung TM, Gandhi SC, Bodmer WF. Hypoxia and lineage specification of cell line-derived colorectal cancer stem cells. Proc Natl Acad Sci USA. 2011;108(11):4382–7.PubMedCentralPubMedGoogle Scholar
  56. 56.
    Liang D, Ma Y, Liu J, et al. The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells. BMC Cancer. 2012;12:201.PubMedCentralPubMedGoogle Scholar
  57. 57.
    Liu L, Ning X, Sun L, et al. Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci. 2008;99(1):121–8.PubMedGoogle Scholar
  58. 58.
    Kato Y, Yashiro M, Fuyuhiro Y, et al. Effects of acute and chronic hypoxia on the radiosensitivity of gastric and esophageal cancer cells. Anticancer Res. 2011;31(10):3369–75.PubMedGoogle Scholar
  59. 59.
    Matsuoka J, Yashiro M, Doi Y, et al. Hypoxia stimulates the EMT of gastric cancer cells through autocrine TGFbeta signaling. PloS One. 2013;8(5):e62310.PubMedCentralPubMedGoogle Scholar
  60. 60.
    Deng B, Zhu JM, Wang Y, et al. Intratumor hypoxia promotes immune tolerance by inducing regulatory T cells via TGF-beta1 in gastric cancer. PLoS One. 2013;8(5):e63777.PubMedCentralPubMedGoogle Scholar
  61. 61.
    Matsumoto K, Arao T, Tanaka K, et al. mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res. 2009;69(18):7160–4.PubMedGoogle Scholar
  62. 62.
    Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11(1):69–82.PubMedGoogle Scholar
  63. 63.
    Ritchie KE, Nor JE. Perivascular stem cell niche in head and neck cancer. Cancer Lett. 2013;338(1):41–6.PubMedGoogle Scholar
  64. 64.
    Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29(30):3968–76.PubMedGoogle Scholar
  65. 65.
    Singh R, Kim WJ, Kim PH, Hong HJ. Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade. Exp Mol Med. 2013;45:e52.PubMedCentralPubMedGoogle Scholar
  66. 66.
    Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999;155(3):739–52.PubMedCentralPubMedGoogle Scholar
  67. 67.
    Shirakawa K, Kobayashi H, Heike Y, et al. Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res. 2002;62(2):560–6.PubMedGoogle Scholar
  68. 68.
    Millimaggi D, Mari M, D’ Ascenzo S, et al. Vasculogenic mimicry of human ovarian cancer cells: role of CD147. Int J Oncol. 2009;35(6):1423–8.PubMedGoogle Scholar
  69. 69.
    Liu Z, Sun B, Qi L, et al. Zinc finger E-box binding homeobox 1 promotes vasculogenic mimicry in colorectal cancer through induction of epithelial-to-mesenchymal transition. Cancer Sci. 2012;103(4):813–20.PubMedGoogle Scholar
  70. 70.
    Wu S, Yu L, Wang D, et al. Aberrant expression of CD133 in non-small cell lung cancer and its relationship to vasculogenic mimicry. BMC Cancer. 2012;12:535.PubMedCentralPubMedGoogle Scholar
  71. 71.
    Yao XH, Ping YF, Bian XW. Contribution of cancer stem cells to tumor vasculogenic mimicry. Protein Cell. 2011;2(4):266–72.PubMedGoogle Scholar
  72. 72.
    Liu TJ, Sun BC, Zhao XL, et al. CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer. Oncogene. 2013;32(5):544–53.PubMedGoogle Scholar
  73. 73.
    Cao Z, Bao M, Miele L, et al. Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-analysis. Eur J Cancer. 2013;49(18):3914–23.PubMedGoogle Scholar
  74. 74.
    Li M, Gu Y, Zhang Z, et al. Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma. Pathol Oncol Res. 2010;16(2):259–66.PubMedGoogle Scholar
  75. 75.
    Jiang J, Liu W, Guo X, et al. IRX1 influences peritoneal spreading and metastasis via inhibiting BDKRB2-dependent neovascularization on gastric cancer. Oncogene. 2011;30(44):4498–508.PubMedCentralPubMedGoogle Scholar
  76. 76.
    Clevers H. Wnt breakers in colon cancer. Cancer cell. 2004;5(1):5–6.PubMedGoogle Scholar
  77. 77.
    Sashikawa Kimura M, Mutoh H, Sugano K. SOX9 is expressed in normal stomach, intestinal metaplasia, and gastric carcinoma in humans. J Gastroenterol. 2011;46(11):1292–9.PubMedGoogle Scholar
  78. 78.
    Ji W, Jiang Z. Effect of shRNA-mediated inhibition of Nanog gene expression on the behavior of human gastric cancer cells. Oncol Lett. 2013;6(2):367–74.PubMedCentralPubMedGoogle Scholar
  79. 79.
    Hutz K, Mejias-Luque R, Farsakova K et al (2014) The stem cell factor SOX2 regulates the tumorigenic potential in human gastric cancer cells. Carcinogenesis.Google Scholar
  80. 80.
    Tlsty TD. Stromal cells can contribute oncogenic signals. Semin Cancer Biol. 2001;11(2):97–104.PubMedGoogle Scholar
  81. 81.
    De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol. 2003;200(4):429–47.PubMedGoogle Scholar
  82. 82.
    Lin SA, Barker N. Gastrointestinal stem cells in self-renewal and cancer. J Gastroenterol. 2011;46(9):1039–55.PubMedGoogle Scholar
  83. 83.
    Schepers AG, Snippert HJ, Stange DE, et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science. 2012;337(6095):730–5.PubMedGoogle Scholar
  84. 84.
    Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev. 2007;17(1):45–51.PubMedGoogle Scholar
  85. 85.
    Katoh M, Kirikoshi H, Terasaki H, Shiokawa K. WNT2B2 mRNA, up-regulated in primary gastric cancer, is a positive regulator of the WNT-beta-catenin-TCF signaling pathway. Biochem Biophy Res Commun. 2001;289(5):1093–8.Google Scholar
  86. 86.
    Clements WM, Wang J, Sarnaik A, et al. beta-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Res. 2002;62(12):3503–6.PubMedGoogle Scholar
  87. 87.
    Nabais S, Machado JC, Lopes C, et al. Patterns of beta-catenin expression in gastric carcinoma: clinicopathological relevance and mutation analysis. Int J Surg Pathol. 2003;11(1):1–9.PubMedGoogle Scholar
  88. 88.
    Kurayoshi M, Oue N, Yamamoto H, et al. Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res. 2006;66(21):10439–48.PubMedGoogle Scholar
  89. 89.
    Yanai K, Nakamura M, Akiyoshi T, et al. Crosstalk of hedgehog and Wnt pathways in gastric cancer. Cancer Lett. 2008;263(1):145–56.PubMedGoogle Scholar
  90. 90.
    de Sousa EM, Vermeulen L, Richel D, Medema JP. Targeting Wnt signaling in colon cancer stem cells. Clin Cancer Res. 2011;17(4):647–53.PubMedGoogle Scholar
  91. 91.
    Cai C, Zhu X. The Wnt/beta-catenin pathway regulates self-renewal of cancer stem-like cells in human gastric cancer. Mol Med Rep. 2012;5(5):1191–6.PubMedGoogle Scholar
  92. 92.
    Ishimoto T, Oshima H, Oshima M, et al. CD44+ slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E2 in gastric tumorigenesis. Cancer Sci. 2010;101(3):673–8.PubMedGoogle Scholar
  93. 93.
    Lewis J. Notch signalling and the control of cell fate choices in vertebrates. Semin Cell Dev Biol. 1998;9(6):583–9.PubMedGoogle Scholar
  94. 94.
    Burns CE, Traver D, Mayhall E, Shepard JL, Zon LI. Hematopoietic stem cell fate is established by the Notch-Runx pathway. Genes Dev. 2005;19(19):2331–42.PubMedCentralPubMedGoogle Scholar
  95. 95.
    Fre S, Huyghe M, Mourikis P, et al. Notch signals control the fate of immature progenitor cells in the intestine. Nature. 2005;435(7044):964–8.PubMedGoogle Scholar
  96. 96.
    Nickoloff BJ, Osborne BA, Miele L. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene. 2003;22(42):6598–608.PubMedGoogle Scholar
  97. 97.
    Fan X, Matsui W, Khaki L, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 2006;66(15):7445–52.PubMedGoogle Scholar
  98. 98.
    Jundt F, Schwarzer R, Dorken B. Notch signaling in leukemias and lymphomas. Curr Mol Med. 2008;8(1):51–9.PubMedGoogle Scholar
  99. 99.
    Yeh TS, Wu CW, Hsu KW, et al. The activated Notch1 signal pathway is associated with gastric cancer progression through cyclooxygenase-2. Cancer Res. 2009;69(12):5039–48.PubMedGoogle Scholar
  100. 100.
    Piazzi G, Fini L, Selgrad M, et al. Epigenetic regulation of Delta-Like1 controls Notch1 activation in gastric cancer. Oncotarget. 2011;2(12):1291–301.PubMedCentralPubMedGoogle Scholar
  101. 101.
    Fukaya M, Isohata N, Ohta H, et al. Hedgehog signal activation in gastric pit cell and in diffuse-type gastric cancer. Gastroenterology. 2006;131(1):14–29.PubMedGoogle Scholar
  102. 102.
    Martin J, Donnelly JM, Houghton J, Zavros Y. The role of sonic hedgehog reemergence during gastric cancer. Dig Dis Sci. 2010;55(6):1516–24.PubMedGoogle Scholar
  103. 103.
    Yoo YA, Kang MH, Kim JS, Oh SC. Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-beta-mediated activation of the ALK5-Smad 3 pathway. Carcinogenesis. 2008;29(3):480–90.PubMedGoogle Scholar
  104. 104.
    Yoo YA, Kang MH, Lee HJ, et al. Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer. Cancer Res. 2011;71(22):7061–70.PubMedGoogle Scholar
  105. 105.
    Song Z, Yue W, Wei B, et al. Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer. PloS One. 2011;6(3):e17687.PubMedCentralPubMedGoogle Scholar
  106. 106.
    Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302(1):1–12.PubMedGoogle Scholar
  107. 107.
    Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. microRNAs in cancer management. Lancet Oncol. 2012;13(6):e249–58.PubMedGoogle Scholar
  108. 108.
    Ueda T, Volinia S, Okumura H, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010;11(2):136–46.PubMedGoogle Scholar
  109. 109.
    Zheng B, Liang L, Wang C, et al. MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res. 2011;17(24):7574–83.PubMedGoogle Scholar
  110. 110.
    Gao P, Xing AY, Zhou GY, et al. The molecular mechanism of microRNA-145 to suppress invasion-metastasis cascade in gastric cancer. Oncogene. 2013;32(4):491–501.PubMedGoogle Scholar
  111. 111.
    Kurashige J, Kamohara H, Watanabe M, et al. MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma. Ann Surg Oncol. 2012;19(Suppl 3):S656–64.PubMedGoogle Scholar
  112. 112.
    Song F, Yang D, Liu B et al (2013) Integrated microRNA network analyses identify a poor-prognosis subtype of gastric cancer characterized by the miR-200 family. Clin Cancer Res.Google Scholar
  113. 113.
    Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–15.PubMedCentralPubMedGoogle Scholar
  114. 114.
    Xia L, Zhang D, Du R, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer: Journal international du cancer. 2008;123(2):372–9.PubMedGoogle Scholar
  115. 115.
    Zhang Y, Lu Q, Cai X. MicroRNA-106a induces multidrug resistance in gastric cancer by targeting RUNX3. FEBS Lett. 2013;587(18):3069–75.PubMedGoogle Scholar
  116. 116.
    Shang Y, Zhang Z, Liu Z et al (2013) miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene.Google Scholar
  117. 117.
    Kong D, Piao YS, Yamashita S, et al. Inflammation-induced repression of tumor suppressor miR-7 in gastric tumor cells. Oncogene. 2012;31(35):3949–60.PubMedGoogle Scholar
  118. 118.
    Ishimoto T, Sugihara H, Watanabe M et al (2013) Macrophage-derived reactive oxygen species suppress miR-328 targeting CD44 in cancer cells and promote redox adaptation. Carcinogenesis.Google Scholar
  119. 119.
    Sugihara H, Ishimoto T, Watanabe M, et al. Identification of miR-30e* regulation of Bmi1 expression mediated by tumor-associated macrophages in gastrointestinal cancer. PloS One. 2013;8(11):e81839.PubMedCentralPubMedGoogle Scholar
  120. 120.
    Ma J, Hong L, Chen Z et al (2013) Epigenetic regulation of microRNAs in gastric cancer. Dig Dis Sci.Google Scholar
  121. 121.
    Roesch A, Fukunaga-Kalabis M, Schmidt EC, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell. 2010;141(4):583–94.PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer Japan 2014

Authors and Affiliations

  • Takatsugu Ishimoto
    • 1
  • Hiroshi Sawayama
    • 1
  • Hidetaka Sugihara
    • 1
  • Hideo Baba
    • 1
  1. 1.Department of Gastroenterological Surgery, Graduate School of Medical ScienceKumamoto UniversityKumamotoJapan

Personalised recommendations